Norden Group LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 21.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 23,172 shares of the healthcare product maker’s stock after selling 6,363 shares during the quarter. Norden Group LLC’s holdings in Abbott Laboratories were worth $2,408,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in ABT. Unique Wealth Strategies LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter valued at about $28,000. Transcendent Capital Group LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $29,000. Richardson Financial Services Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $29,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $30,000. Finally, True Wealth Design LLC boosted its position in shares of Abbott Laboratories by 1,677.8% during the 4th quarter. True Wealth Design LLC now owns 320 shares of the healthcare product maker’s stock valued at $35,000 after acquiring an additional 302 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.
Abbott Laboratories Trading Up 0.7 %
Shares of ABT traded up $0.76 on Friday, reaching $113.86. 3,802,320 shares of the company’s stock were exchanged, compared to its average volume of 5,855,512. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $198.07 billion, a P/E ratio of 35.47, a price-to-earnings-growth ratio of 2.82 and a beta of 0.72. The business has a 50 day moving average price of $107.87 and a two-hundred day moving average price of $108.79. Abbott Laboratories has a 12 month low of $89.67 and a 12 month high of $121.64.
Abbott Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Monday, July 15th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 1.93%. The ex-dividend date of this dividend was Monday, July 15th. Abbott Laboratories’s payout ratio is presently 68.54%.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. The Goldman Sachs Group started coverage on shares of Abbott Laboratories in a research report on Thursday, May 30th. They set a “buy” rating and a $121.00 target price on the stock. Evercore ISI reduced their price target on shares of Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price target on shares of Abbott Laboratories in a research report on Tuesday, June 4th. Citigroup boosted their price target on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, Edward Jones lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.80.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
See Also
- Five stocks we like better than Abbott Laboratories
- Most Volatile Stocks, What Investors Need to Know
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.